CClinicalTrials.gg
RecruitingNCT05494983Updated Jan 30, 2024

Pain, Sleep and Gut Microbiota

An interventional study of Screening visit and Peripheral sensitization session in Sensitization, Central, Peripheral Sensitization and Gut Microbiota, sponsored by Université Catholique de Louvain. Recruiting at 1 site in Belgium. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-30.

Sponsored by Université Catholique de Louvain · Not applicable, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started Jul 2022; still recruiting 4 years 3 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The objective of this study in healthy volunteers is to evaluate whether the composition of the gut microbiota and sleep quality influence the susceptibility to develop peripheral and central sensitization of pain pathways.

In two different experimental sessions, the following factors will be tested: the influence of the composition of the gut microbiota on the susceptibility to develop peripheral sensitization of nociceptors, and the susceptibility to develop central sensitization of pain pathways. To assess susceptibility to peripheral sensitization, a solution of capsaicin (the active component of chili pepper) will be applied to the skin to induce neurogenic inflammation produced by the release of substances from nociceptors at the peripheral level. This neurogenic inflammation is characterized by a transient redness of the skin that will be measured with an infrared camera. To evaluate the susceptibility to sensitization at the central level, a high frequency electrical stimulation will be applied to the skin. This stimulation induces an increase in sensitivity to mechanical stimulation secondary to central sensitization. The intensity, extent and duration of this mechanical hyperalgesia will therefore be used as a measure of susceptibility to central sensitization.

A stool sample and a blood sample will be taken. These samples will be used to characterize the composition of the intestinal microbiota, as well as the metabolites produced by this microbiota. These analyses will allow a comparison of the composition of the microbiota and the metabolites in subjects with a tendency to develop low vs. high sensitization at the peripheral and central levels.

Similarly, sleep quality and average sleep duration will be assessed using questionnaires and a measurement of the participant's activity using a wrist movement sensitive bracelet. This information will be used to assess whether some of the interindividual variability in developing peripheral or central sensitization might be related to differences in sleep quality.

Finally, systemic inflammation could be a factor modulated by sleep and gut microbiota, influencing pain perception and susceptibility to sensitization. For this reason, systemic pro- and anti-inflammatory cytokines will be measured in the blood sample.

02

Conditions studied

  • Sensitization, Central
  • Peripheral Sensitization
  • Gut Microbiota
  • Sleep Quality
03

In context

Lead sponsor

Université Catholique de Louvain is the lead sponsor of 144 studies on the registry; 57 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Aged between 18 and 65 years
  • Ability to provide written informed consent
  • Understanding French

Exclusion criteria

Exclusion Criteria:

  • Current or recent (\< 2 months) use of antibiotics, probiotics, fiber supplements or any other molecule that modifies intestinal transit.
  • Current or recent (\< 1 month) use of non-steroidal anti-inflammatory drugs and glucocorticoids
  • Not willing or able to abstain from acute alcohol intoxication from 7 days prior to each of the two study sessions.
  • Consumption of alcohol 24 hours prior to each of the two study sessions.
  • Consumption of hypnotics, centrally-acting analgesics or psychotropic drugs.
  • Obesity: body mass index > 30 kg.m-2
  • Pregnancy and breast-feeding
  • Diabetes
  • Cancer
  • History of inflammatory bowel disease
  • History of weight-loss surgery (e.g., gastric bypass, gastric band)
  • History of autoimmune disease (e.g., lupus, rheumatoid arthritis)
  • Evidence for any other clinically significant disease on direct questioning.
  • Being a volleyball player due to risk of modified sensitivity of the volar forearm skin.
  • Any implanted medical device such as cardiac pacemakers, cochlear implants and medication pumps.
  • Dermatological condition affecting the skin of the volar forearms.
  • History of an allergy to chili peppers/capsaicin.
  • Any other reason to exclude the subject according to judgment by the investigator.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
140 participants (estimated)

Study arms

  • Other
    Session 1 : Peripheral Session (left) - session 2 Central Session (right)

    The susceptibility to develop peripheral sensitization will be assessed at the first experimental session, the stimulation will occur at the left forearm. The susceptibility to develop central sensitization will be assessed at the second experimental session, the stimulation will occur at the right forearm. In both experimental sessions, participants will have to fill questionnaires about the use of medications, the Stanford Sleepiness Scale, the Leeds Sleep Evaluation Questionnaire, and the first part of the State and Trait Anxiety Questionnaire. During sensory stimulation, an infrared camera will be used to measure pupil diameter which constitute an indirect correlate of stimulus-evoked phasic variations in activity of the locus coeruleus. In order to measure autonomic reactivity to pain stimuli, the heart rate variability will be measured by recording electrocardiography.

    Other: Screening visit · Other: Peripheral sensitization session · Other: Central sensitization session

  • Other
    Session 1 : Peripheral Session (right) - session 2 Central Session (left)

    The susceptibility to develop peripheral sensitization will be assessed at the first experimental session, the stimulation will occur at the right forearm. The susceptibility to develop central sensitization will be assessed at the second experimental session, the stimulation will occur at the left forearm. In both experimental sessions, participants will have to fill questionnaires about the use of medications, the Stanford Sleepiness Scale, the Leeds Sleep Evaluation Questionnaire, and the first part of the State and Trait Anxiety Questionnaire. During sensory stimulation, an infrared camera will be used to measure pupil diameter which constitute an indirect correlate of stimulus-evoked phasic variations in activity of the locus coeruleus. In order to measure autonomic reactivity to pain stimuli, the heart rate variability will be measured by recording electrocardiography.

    Other: Screening visit · Other: Peripheral sensitization session · Other: Central sensitization session

  • Other
    Session 1 : Central Session (left) - session 2 Peripheral Session (right)

    The susceptibility to develop central sensitization will be assessed at the first experimental session, the stimulation will occur at the left forearm. The susceptibility to develop peripheral sensitization will be assessed at the second experimental session, the stimulation will occur at the right forearm. In both experimental sessions, participants will have to fill questionnaires about the use of medications, the Stanford Sleepiness Scale, the Leeds Sleep Evaluation Questionnaire, and the first part of the State and Trait Anxiety Questionnaire. During sensory stimulation, an infrared camera will be used to measure pupil diameter which constitute an indirect correlate of stimulus-evoked phasic variations in activity of the locus coeruleus. In order to measure autonomic reactivity to pain stimuli, the heart rate variability will be measured by recording electrocardiography.

    Other: Screening visit · Other: Peripheral sensitization session · Other: Central sensitization session

  • Other
    Session 1 : Central Session (right) - session 2 Peripheral Session (left)

    The susceptibility to develop central sensitization will be assessed at the first experimental session, the stimulation will occur at the right forearm. The susceptibility to develop peripheral sensitization will be assessed at the second experimental session, the stimulation will occur at the left forearm. In both experimental sessions, participants will have to fill questionnaires about the use of medications, the Stanford Sleepiness Scale, the Leeds Sleep Evaluation Questionnaire, and the first part of the State and Trait Anxiety Questionnaire. During sensory stimulation, an infrared camera will be used to measure pupil diameter which constitute an indirect correlate of stimulus-evoked phasic variations in activity of the locus coeruleus. In order to measure autonomic reactivity to pain stimuli, the heart rate variability will be measured by recording electrocardiography.

    Other: Screening visit · Other: Peripheral sensitization session · Other: Central sensitization session

Interventions

  • OtherScreening visit

    The participants will be screened for inclusion and exclusion criteria and will be asked to fill the following questionnaires : Pittsburgh Sleep Quality Index, State and Trait Anxiety Questionnaire, Pain Catastrophizing Scale Fear of Pain Questionnaire, Perceived Stress Scale, Beck Depression Inventory, and questionnaires to assess their health status and the use of medications. A blood sample (to measure pro- and anti-inflammatory cytokines and perform metabolomic analyses) will be obtained. Enrolled participants will be given a wearable actimeter to assess daily total sleep duration during one week before the first experimental session. They will also be requested to complete daily a sleep diary during one week before each experimental session, and a food diary before the first experimental session. A fecal sample (to assess gut microbiota composition and perform metabolomic analyses) will be collected between the screening visit and the first experimental session.

  • OtherPeripheral sensitization session

    The extent of neurogenic inflammation induced by topical capsaicin will be used as a measure of the susceptibility to sensitize at peripheral level. A solution of capsaicin will be applied to the skin of the left or right volar forearm for 30 minutes. The capsaicin-induced neurogenic inflammation can be quantified by assessing the intensity, extent and duration of the capsaicin-induced cutaneous flare response using thermal infrared imaging. Using heat stimuli delivered to the treated skin and surrounding skin, the intensity and duration of the capsaicin-induced hyperalgesia will also be assessed. The experimental session will last approximately two hours.

  • OtherCentral sensitization session

    The extent of secondary mechanical hyperalgesia induced by high-frequency electrical stimulation (HFS) of the skin of the left or right volar forearm will be used as a measure of the susceptibility to develop central sensitization. The stimulation will be delivered using a multi-pin electrode designed to preferentially activate epidermal free nerve endings. The strength, spatial extent and duration of the HFS-induced changes in pinprick sensitivity will be characterized by using calibrated mechanical pinprick stimuli. The experimental session will last approximately one hour.

06

What researchers measure

Primary outcomes

  1. Correlation between composition of the intestinal microbiota and its metabolites and the susceptibility of sensitization at the peripheral and central levels.

    A stool sample and a blood sample will be taken. These samples will be used to characterize the composition of the intestinal microbiota, as well as the metabolites produced by this microbiota. These analyses will allow a comparison of the composition of the microbiota and the metabolites in subjects with a tendency to develop low vs. high sensitization at the peripheral and central levels. The gut microbiota composition will be analyzed using 16S rDNA sequencing. Untargeted metabolite profiling, in fecal and blood samples, will be performed using liquid chromatography (LC) coupled with tandem mass spectrometry (MS-MS) platforms.

    Time frame: one week

  2. Correlation between sleep quality and the susceptibility of sensitization at the peripheral and central levels.

    Sleep quality will be assessed using questionnaires and a measurement of the participant's sleep using a wrist movement sensitive bracelet. This information will be used to assess whether some of the inter-individual variability in developing peripheral or central sensitization might be related to differences in sleep quality.

    Time frame: five weeks

  3. Correlation between sleep duration and the susceptibility of sensitization at the peripheral and central levels.

    Average sleep duration will be assessed using questionnaires and a measurement of the participant's sleep using a wrist movement sensitive bracelet. This information will be used to assess whether some of the inter-individual variability in developing peripheral or central sensitization might be related to differences in sleep duration.

    Time frame: five weeks

Secondary outcomes

  1. Correlation between levels of systemic pro- and anti-inflammatory cytokines measured by multiplex assays and the susceptibility of sensitization at the peripheral and central levels.

    Systemic inflammation could be an important factor modulated by sleep and the gut microbiota, influencing nociception and sensitization at peripheral and central levels. Plasma concentrations (pg/mL) of several pro-inflammatory (TNFa, IL-6, IL-1b, MCP-1) and anti-inflammatory (IL-10) markers will me measured using commercially available multiplex assays.

    Time frame: one week

  2. Correlation between pupil diameter and the susceptibility of sensitization at the peripheral and central levels.

    During sensory stimulation, an infrared camera will be used to measure pupil diameter which has been shown to constitute an indirect correlate of stimulus-evoked phasic variations in activity of the locus coeruleus.

    Time frame: five weeks

  3. Correlation between heart rate variability and the susceptibility of sensitization at the peripheral and central levels.

    In order to measure autonomic reactivity to pain stimuli, the heart rate variability will be measured by recording electrocardiography during experimental sessions.

    Time frame: five weeks

07

Study locations

1 of 1 sites recruiting
  • UCLouvain, IONS
    Woluwe-Saint-Lambert, 1200, Belgium
    • André Mouraux, MD, PhD · Contact · andre.mouraux@uclouvain.be
    • Gwenaëlle Mievis, PhD Student · Contact · gwenaelle.mievis@uclouvain.be
    • André Mouraux, MD, PhD · Principal investigator
    • Sophie Leclercq, PhD · Sub investigator
    • Gwenaëlle Mievis, PhD Student · Sub investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05494983
Lead sponsor
Université Catholique de Louvain
Responsible party
Sponsor
First posted
Aug 10, 2022
Start date
Jul 4, 2022
Primary completion
Jun 30, 2025 (estimated)
Completion
Jan 4, 2026 (estimated)
Last update
Jan 30, 2024

Study contacts

Gwenaëlle Mievis, PhD Student
Contact
gwenaelle.mievis@uclouvain.be
+32488451915
André Mouraux, MD, PhD
principal investigator · UCLouvain, IONS

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion